MiMedx

At the request of the Centers for Medicare and Medicaid Services (CMS), the Federal Agency for Healthcare Research and Quality (AHRQ) sponsored a technical brief evaluating 245 published studies of skin substitutes from 76 manufacturers. · 22 of the 245 studies met the criteria to be a Randomized Controlled Trial (RCT) · 12 of these 22 RCTs met the inclusion criteria for “low risk-of-bias” · 9 of these 12 studies met primary endpoints 56% of the low risk-of-bias studies that met primary endpoints were on MIMEDX’s products. MIMEDX study quality was validated as best in class. Learn more: https://bit.ly/41W4WdM #MIMEDX #RCT #Research #SkinSubstitutes

With a unique deferred payment model and expert clinical documentation support, the WoundGenex Premier Graft Purchasing Program can transform your approach to wound care. MIMEDX and WoundGenex are committed to supporting private practice healthcare professionals like you with innovative solutions that prioritize both patient outcomes and provider feasibility. Get started today: https://lnkd.in/ea8cYFqU #MIMEDX #WoundGenex #SkinSubstitutes #WoundCare #Reimbursement

EPIFIX (Q4186) and EPICORD (Q4187) by MIMEDX continue to be covered under the newly published Future Effective Local Coverage Determinations (LCDs) by all 7 Medicare Administrative Contractors (MACs).   This ensures uninterrupted access to our best-in-class skin substitutes, supporting patient care across the nation. For more details, view our LCD resources here: https://lnkd.in/ehXBFVtj   #MIMEDX #EPIFIX #EPICORD #SkinSubstitutes #MedicareCoverage #HealthcareInnovation

When it comes to challenging wounds, patients could be waiting too long for closure. If wounds stall with standard of care, escalate to an advanced treatment with a MIMEDX allograft. Don’t Risk the Wait: Begin with EPIFIX® today! https://bit.ly/3RCh28j #MIMEDX #EPIFIX #WoundCare #PatientOutcomes

Meet Dodou, a patient with a large diabetic foot ulcer that his physician treated with EPICORD®, a dehydrated human umbilical cord allograft. EPICORD provides a protective environment to support the healing process. Learn more about EPICORD: https://bit.ly/4afgQDg #MIMEDX #EPICORD #Diabetes #DFU #WoundCare

Did you know that MIMEDX has the most Level I RCTs of any placental allograft company? With seven RCTs demonstrating the safety and efficacy of EPIFIX® and EPICORD®, we are empowering clinicians with evidence to enhance patient outcomes. Learn more about the science behind our advanced wound and surgical solutions: https://bit.ly/3v2A52R #MIMEDX #RCT #ClinicalResearch #WoundCare

Are the skin substitutes you use supported by robust “evidence”? In 2020, at the request of CMS, the AHRQ did a review of the available skin substitute evidence. Here is a summary of what they found: https://bit.ly/41W4WdM #MIMEDX #EPIFIX #EPICORD

In the field of wound care, the challenges of ensuring optimal patient outcomes while managing financial constraints are ever-present. The WoundGenex Premier Graft Purchasing Program is a pioneering solution designed to address these challenges head-on. Would you like to learn how your private practice can order premium MIMEDX allografts with NO UPFRONT COST? Click here: https://lnkd.in/ea8cYFqU #MIMEDX #WoundGenex #SkinSubstitutes #WoundCare #Reimbursement

Matt Bardin, PharmD, BCPS presented NEW clinical evidence on a co-authored poster with Dr. Nezar Jrebi that showed a positive impact of AMNIOFIX® in colorectal anastomoses. Patients treated with AMNIOFIX experienced a lower anastomotic leak rate than the control group¹ which has been reported to help significantly reduce postoperative complications and healthcare costs.²⁻³ Curious about how colorectal surgery outcomes have been improved in AMNIOFIX recipients? https://bit.ly/48CYPhZ #MIMEDX #AMNIOFIX #Surgery #ColorectalSurgery #PlacentalAllografts

As we celebrate Thanksgiving, we extend heartfelt thanks to our dedicated team and healthcare providers. Your commitment changes lives daily.    #Thanksgiving #Gratitude